Tarsus Pharmaceuticals Inc (NAS:TARS)
$ 28.93 1.38 (5.01%) Market Cap: 1.09 Bil Enterprise Value: 825.02 Mil PE Ratio: 0 PB Ratio: 3.97 GF Score: 60/100

Tarsus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 06:30PM GMT
Release Date Price: $19.11 (+1.76%)
Bobby Azamian
Tarsus Pharmaceuticals, Inc. - CEO

Hello, everyone. My name is Bobby Azamian. I'm the CEO of Tarsus Pharmaceuticals, and I'm excited to give you an update today. So we sit here today less than three months from our producer date. And so I want to make sure to hit the high points on what Tarsus is. And I think the uniqueness of Tarsus is, we are creating a category with a curative product. And we will talk more about that. And I think that leads us to a lot of really strong fundamentals for our launch upcoming.

We understand how to launch a product. Our team has decades of experience really blending eyecare leadership and biotech launch experience. And finally, we're going to focus on the launch today, but there's more to Tarsus's story. We have a Phase 2 pipeline across three products with two of those reading out later this year.

So a lot of you know about eye care, but let me just level set. So we all know our eyes are important, our vision is very important to us. What might not be as well known is the front of the eye is actually the bigger part of the market. That's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot